Eli Lilly and Company

Jeffrey Daniel Cohen

Daniel Jon Sall

Jolie Anne Bastian

Almudena Rubio

Louis Nickolaus Jungheim

Brian Stephen Muehl

Timothy Alan Shepherd

Kenneth Jeff Thrasher

Jennifer Anne McMahon

Stephen A Hitchcock

James Robert Henry

William Thomas McMillen

William Wilson Turner, Jr

Peter S Borromeo

Daniel Ray Mayhugh

Gaiying Zhao

George Stuart Gregory

Stacy Kay Henle

Bradley Earl Reaman

Jiehao Chen

Henry U Bryant

Jeffrey A Dodge

Alan David Palkowitz

Vinod Francis Patel

Philip Arthur Hipskind

Ho-Shen Lin

Bryan Hurst Norman

Michael Enrico Richett

Kennan Joseph Fahey

Charles Willis Lugar, Iii

Karen Lynn Lobb

Rosanne Bonjouklian

Jeremy Schulenburg York

Roger L Robey

James Densmore Copp

Julian Stanley Kroin

Mark Louis Heiman

Charles A Alt

Kenneth Lee Hauser

Andrew Michael Ratz

Peter Ambrose Lander

Gary A Rhodes

Joseph Michael Gruber

Brandon Lee Parkhurst

William Harlan Gritton

Takako Wilson (nee Takakuwa)

William George Trankle

Scott Alan Jones

David E Seyler

Takako Wilson

Sreenivasarao Vepachedu

Mark Christopher Lohman

Douglas Webb Johnson

Michelle Lee Thompson

Julia Marie Clay

Yongping Xie

Joseph Henry Kennedy

Qiupang Wang

Wesley Todd White

Jennifer Anne Mcmahon

William Thomas Mcmillen

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts, pharmaceutical compositions, uses, and methods of use thereof are provided.

Selective estrogen receptor degraders

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either Ror Ris independently selected from Cl, F, —CF, or —CH, and the other is hydrogen, and methods for their use are provided.

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either Ror Ris independently selected from Cl, F, &#x2014;CF, or &#x2014;CH, and the other is hydrogen, and methods for their use are provided.

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. 

1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.

2,3-dihydro-1H-indole compounds

The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C&#x2014;Ror N; Ris hydrogen, fluoro or cyano; Ris formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; Ris methyl or trifluoromethyl; Ris pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; Ris trifluoromethyl or methylsulfonyl; Ris hydrogen or methyl; and R, R, R, Rand Rare independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R, R, R, Rand Rare hydrogen useful in the treatment of cancer. 

Tetrasubstituted pyridazine hedgehog pathway antagonists

The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1 

Compounds and pharmaceutical compositions for inhibiting MRP1

This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.

Growth hormone secretagogues

A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.

Ring modified cyclic peptide analogs

The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).

Methods and compounds for inhibiting MRP1

A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal omithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.

Growing community of inventors

Indianapolis, IN, United States of America

Jeffrey Daniel Cohen